Apixaban or Enoxaparin After Head and Neck Cancer Surgery

Part of paid clinical trials in Syracuse, New York.

Sponsor
Kiranya Arnold
Study ID
NCT07189897
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • Enoxaparin — DRUG
    For DVT prophylaxis
  • Apixaban — DRUG
    For DVT prophylaxis

Study Details

The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine? Researchers will compare 2 groups: One group will take apixaban (a pill taken twice a day) for 10 days after surgery. The other group will take enoxaparin (a shot given once a day) for 10 days after surgery. Participants will: Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks How long will participation last? About 4 months from surgery through the last follow-up visit.

Key Dates

Start date
Oct 31, 2025
Status verified
Oct 2025
Primary completion
Sep 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
76 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Control: Enoxaparin
    40 mg subcutaneous enoxaparin given once daily for DVT prevention.
  • Experimental: Experimental: Apixaban
    2.5 mg oral apixaban given twice daily for DVT prevention.

Primary Outcome Measure

Study enrollment rate. [ Time Frame: From study start until target enrollment is reached (up to 24 months). ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
SUNY UpstateSyracuseNew York13210
Laine Abernathy
[email protected]
315-464-5980

Find similar trials in Syracuse, NY

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
SUNY Upstate· Syracuse, NY

Related Studies